Description

The conversation delves into the rediscovery of ApoB as a significant cardiovascular marker and its suspiciously aligned timing with pharmaceutical profit motives. It explores the comparison between ApoB and LDLC, the rise of statins, the emergence of PCSK9 inhibitors, the controversy around ApoB, the context of metabolic dysfunction, and the pharmaceutical vs. metabolic approach to ApoB. It concludes with the distinction between treating a number and treating a disease.

Takeaways

• ApoB has become a significant cardiovascular marker
• The timing of ApoB's rediscovery is suspiciously aligned with pharmaceutical profit motives

Chapters

• 00:00 Treating a Number vs. Treating a Disease